For the quarter ending 2025-09-30, KBLB made $1,533,433 in revenue. -$1,509,566 in net income. Net profit margin of -98.44%.
| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
|---|---|---|---|---|
| General and administrative | 1,199,955 | 344,035 | 308,851 | 222,274.5 |
| Professional fees | 38,533 | 43,625 | 63,035 | 72,596.5 |
| Revenue | - | 0 | - | - |
| Officers salary | 186,157 | 186,197 | 184,730 | 242,446 |
| Research and development | 9,243 | 63,888 | 23,876 | 44,996 |
| Total operating expenses | 1,433,888 | 637,745 | 580,492 | 582,313 |
| Loss from operations | -1,433,888 | -637,745 | -580,492 | -582,313 |
| Net change in unrealized depreciation on investment in gold bullion | 30,968 | 10,011 | -117,488 | -17,391.5 |
| Interest expense | 144,255 | 141,986 | 140,348 | 132,237.667 |
| Gain on sale of gold | 98,427 | 62,469 | - | - |
| Impairment of right-of-use asset | - | 0 | - | - |
| Interest income | 1,118 | 1,140 | 3,319 | 18,804.333 |
| Total other income/(expenses) | -75,678 | -88,388 | -19,541 | -97,462 |
| Net (loss) before provision for income taxes | -1,509,566 | -726,133 | -600,033 | -679,775 |
| Provision for income taxes | - | 0 | - | - |
| Net (loss) | -1,509,566 | -726,133 | -600,033 | -679,775 |
| Net income (loss) per share - basic | 0 | 0 | 0 | 0 |
| Net income (loss) per share - diluted | 0 | 0 | 0 | 0 |
| Weighted average number of shares outstanding during the period - basic | 1,068,264,462 | 1,047,493,242 | 1,041,458,063 | -519,187,109.5 |
| Weighted average number of shares outstanding during the period - diluted | 1,068,264,462 | 1,047,493,242 | 1,041,458,063 | -519,187,109.5 |
Kraig Biocraft Laboratories, Inc. (KBLB)
Kraig Biocraft Laboratories, Inc. (KBLB)